Literature DB >> 10656439

Correlations among p53, Her-2/neu, and ras overexpression and aneuploidy by multiparameter flow cytometry in human breast cancer: evidence for a common phenotypic evolutionary pattern in infiltrating ductal carcinomas.

C A Smith1, A A Pollice, L P Gu, K A Brown, S G Singh, L E Janocko, R Johnson, T Julian, D Hyams, N Wolmark, L Sweeney, J F Silverman, S E Shackney.   

Abstract

Human solid tumors develop multiple genetic abnormalities that accumulate progressively in individual cells during the course of tumor evolution. We sought to determine whether there are specific sequences of occurrence of these progressive evolutionary changes in human breast cancers by performing correlated cell-by-cell measurements of cell DNA content, p53 protein, Her-2/neu protein, and ras protein by multiparameter flow cytometry in 56 primary tumor samples obtained at surgery. In addition, p53 allelic loss and Her-2/neu gene amplification were determined by fluorescence in situ hybridization in cells from the same samples. We reasoned that if there is a specific order in which genetic changes occur, the same early changes would be found consistently in the cells with the fewest abnormalities. We reasoned further that late-developing abnormalities would not occur alone in individual cells but would almost always be found together with the early changes inherited by the same cells. By these criteria, abnormalities involving p53 generally occurred early in the course of development of invasive breast cancers, whereas ras protein overexpression was found to be a late-occurring phenomenon. Within individual tumors, cellular p53 overexpression was often observed alone in individual cells, whereas ras protein overexpression was rarely observed in the absence of p53 overexpression and/or Her-2/neu overexpression in the same cells. Furthermore, the intracellular level of each abnormally expressed protein was found to increase progressively as new abnormalities were acquired. Infiltrating ductal carcinomas exhibited characteristic phenotypic patterns in which p53 allelic loss and/or p53 protein overexpression, Her-2/neu amplification and/or overexpression, aneuploidy, and ras overexpression accumulated within individual cells. However, this pattern was not a prominent feature of lobular breast cancers. All six lobular breast cancers studied were diploid. p53 allelic loss and/or early p53 overexpression, and late ras cooverexpression in the same cells were less common in lobular breast cancers than in infiltrating ductal carcinomas. Although Her-21neu overexpression was a common finding in lobular breast cancers, Her-2/neu amplification was not observed in these tumors.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10656439

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  11 in total

1.  Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel.

Authors:  Kimberly J Bussey; Koei Chin; Samir Lababidi; Mark Reimers; William C Reinhold; Wen-Lin Kuo; Fuad Gwadry; Hosein Kouros-Mehr; Jane Fridlyand; Ajay Jain; Colin Collins; Satoshi Nishizuka; Giovanni Tonon; Anna Roschke; Kristen Gehlhaus; Ilan Kirsch; Dominic A Scudiero; Joe W Gray; John N Weinstein
Journal:  Mol Cancer Ther       Date:  2006-04       Impact factor: 6.261

2.  Treatment effects of the EGFR pathway drugs on head and neck cancer stem cells.

Authors:  Glaucia Maria de Mendonça Fernandes; Vilson Serafim Junior; Ana Lívia Silva Galbiatti-Dias; Leticia Antunes Muniz Ferreira; Márcia Maria Urbanin Castanhole-Nunes; Rosa Sayoko Kawasaki-Oyama; José Victor Maniglia; Erika Cristina Pavarino; Eny Maria Goloni-Bertollo
Journal:  Am J Cancer Res       Date:  2022-09-15       Impact factor: 5.942

3.  Phase II trial of tipifarnib plus neoadjuvant doxorubicin-cyclophosphamide in patients with clinical stage IIB-IIIC breast cancer.

Authors:  Joseph A Sparano; Stacy Moulder; Aslamuzzaman Kazi; Domenico Coppola; Abdissa Negassa; Linda Vahdat; Tianhong Li; Christine Pellegrino; Susan Fineberg; Pam Munster; Mokenge Malafa; David Lee; Shira Hoschander; Una Hopkins; Dawn Hershman; John J Wright; Celina Kleer; Sofia Merajver; Said M Sebti
Journal:  Clin Cancer Res       Date:  2009-04-07       Impact factor: 12.531

4.  Characteristic genome rearrangements in experimental evolution of Saccharomyces cerevisiae.

Authors:  Maitreya J Dunham; Hassan Badrane; Tracy Ferea; Julian Adams; Patrick O Brown; Frank Rosenzweig; David Botstein
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-21       Impact factor: 11.205

Review 5.  The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies.

Authors:  Jaclyn A Freudenberg; Qiang Wang; Makoto Katsumata; Jeffrey Drebin; Izumi Nagatomo; Mark I Greene
Journal:  Exp Mol Pathol       Date:  2009-05-18       Impact factor: 3.362

6.  Phase I-II study of the farnesyl transferase inhibitor tipifarnib plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in HER2/neu-negative inflammatory carcinoma and non-inflammatory estrogen receptor-positive breast carcinoma.

Authors:  Eleni Andreopoulou; Ivette S Vigoda; Vicente Valero; Dawn L Hershman; George Raptis; Linda T Vahdat; Hyo S Han; John J Wright; Christine M Pellegrino; Massimo Cristofanilli; Ricardo H Alvarez; Karen Fehn; Susan Fineberg; Joseph A Sparano
Journal:  Breast Cancer Res Treat       Date:  2013-09-26       Impact factor: 4.872

7.  Inference of tumor phylogenies from genomic assays on heterogeneous samples.

Authors:  Ayshwarya Subramanian; Stanley Shackney; Russell Schwartz
Journal:  J Biomed Biotechnol       Date:  2012-05-13

8.  Applying unmixing to gene expression data for tumor phylogeny inference.

Authors:  Russell Schwartz; Stanley E Shackney
Journal:  BMC Bioinformatics       Date:  2010-01-20       Impact factor: 3.169

Review 9.  Recent Advances in the Treatment of Breast Cancer.

Authors:  Christy W S Tong; Mingxia Wu; William C S Cho; Kenneth K W To
Journal:  Front Oncol       Date:  2018-06-14       Impact factor: 6.244

10.  The Targeted Therapies Era Beyond the Surgical Point of View: What Spine Surgeons Should Know Before Approaching Spinal Metastases.

Authors:  Fabio Cofano; Matteo Monticelli; Marco Ajello; Francesco Zenga; Nicola Marengo; Giuseppe Di Perna; Roberto Altieri; Paola Cassoni; Luca Bertero; Antonio Melcarne; Fulvio Tartara; Alessandro Ducati; Diego Garbossa
Journal:  Cancer Control       Date:  2019 Jan-Dec       Impact factor: 3.302

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.